Cargando…

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells

Steroid receptor coactivator 3 (SRC-3/NCoA3/AIB1), is a key regulator of gene transcription and it plays a central role in breast cancer (BC) tumorigenesis, making it a potential therapeutic target. Beyond its function as an important regulator of estrogen receptor transcriptional activity, SRC-3 al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilad, Yosi, Eliaz, Yossi, Yu, Yang, Dean, Adam M., Han, San Jung, Qin, Li, O’Malley, Bert W., Lonard, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994904/ https://www.ncbi.nlm.nih.gov/pubmed/33767353 http://dx.doi.org/10.1038/s42003-021-01929-1

Ejemplares similares

Reply to: Target expression is a relevant factor in synthetic lethal screens
por: Gilad, Yosi, et al.
Publicado: (2022)

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2019)

Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2020)

Steroid receptor coactivators – their role in immunity
por: Gilad, Yosi, et al.
Publicado: (2022)

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
por: Gilad, Yosi, et al.
Publicado: (2021)

Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2022)

Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
por: Kiessling, Michael K., et al.
Publicado: (2016)

Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1
por: Li, Chao, et al.
Publicado: (2011)

SRC-2 Coactivator: a role in human metabolic evolution and disease
por: O’Malley, Bert W.
Publicado: (2020)

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
por: Bijou, Imani, et al.
Publicado: (2023)

Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs
por: Nikolai, Bryan C., et al.
Publicado: (2021)

Quantitative evaluation of incomplete preweaning lethality in mice by using the CRISPR/Cas9 system
por: Nakamura, Takumi, et al.
Publicado: (2018)

Wound Healing-related Functions of the p160 Steroid Receptor Coactivator Family
por: Mullany, Lisa K, et al.
Publicado: (2020)

Enhancer–promoter entanglement explains their transcriptional interdependence
por: Panigrahi, Anil K., et al.
Publicado: (2023)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
por: Castells-Roca, Laia, et al.
Publicado: (2021)

CRISPR/Cas9-Mediated Knock-Out of dUTPase in Mice Leads to Early Embryonic Lethality
por: Pálinkás, Hajnalka Laura, et al.
Publicado: (2019)

Synthetic CRISPR/Cas9 reagents facilitate genome editing and homology directed repair
por: DiNapoli, Sara E, et al.
Publicado: (2020)

Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9
por: Montefiori, Lindsey, et al.
Publicado: (2017)

What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug
por: Song, Xianzhou, et al.
Publicado: (2015)

The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)

Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
por: Krill-Burger, J. Michael, et al.
Publicado: (2023)

Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment
por: Han, Sang Jun, et al.
Publicado: (2022)

Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors
por: Wang, Hong, et al.
Publicado: (2018)

Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC
por: Kwon, Deborah Y., et al.
Publicado: (2017)

A fly model establishes distinct mechanisms for synthetic CRISPR/Cas9 sex distorters
por: Fasulo, Barbara, et al.
Publicado: (2020)

Synthetic Circular gRNA Mediated Biological Function of CRISPR-(d)Cas9 System
por: Wang, Mingxia, et al.
Publicado: (2022)

Recent Advances in CRISPR-Cas Technologies for Synthetic Biology
por: Jeong, Song Hee, et al.
Publicado: (2023)

CRISPR/Cas9 in Gastrointestinal Malignancies
por: Jefremow, André, et al.
Publicado: (2021)

Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
por: Liu, Jing, et al.
Publicado: (2021)

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment
por: Paul, James M., et al.
Publicado: (2016)

Generating viable mice with heritable embryonically lethal mutations using the CRISPR-Cas9 system in two-cell embryos
por: Wu, Yi, et al.
Publicado: (2019)

CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Engineering large-scale chromosomal deletions by CRISPR-Cas9
por: Eleveld, Thomas F, et al.
Publicado: (2021)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering
por: Lee, Kunwoo, et al.
Publicado: (2017)

Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation
por: Shen, Chih-Che, et al.
Publicado: (2019)

Synthetic molecular sensors based on CRISPR‐Cas9 redirect anticancer signal flows to treat retinoblastomas
por: Xiao, Lulu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6gdb5gj8582f351dfjkvi3o3ji